Compare SOUN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOUN | AGIO |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | 954 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | N/A | 2013 |
| Metric | SOUN | AGIO |
|---|---|---|
| Price | $6.17 | $35.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $15.00 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 31.9M | 1.0M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $40.76 | $76.75 |
| Revenue Next Year | $20.02 | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.83 | $22.24 |
| 52 Week High | $22.17 | $46.00 |
| Indicator | SOUN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 44.85 |
| Support Level | $6.02 | $26.16 |
| Resistance Level | $7.09 | $36.07 |
| Average True Range (ATR) | 0.36 | 1.75 |
| MACD | 0.02 | -0.83 |
| Stochastic Oscillator | 22.10 | 6.93 |
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.